ASLAN Pharmaceuticals Announces Participation in January Investor Conferences
ASLAN Pharmaceuticals (Nasdaq: ASLN) has announced its participation in several key conferences in January 2023. These events, including the BIO Partnering Conference and the 12th Annual LifeSci Partners Corporate Access Event, aim to facilitate one-on-one meetings with investors. The company is also focusing on its clinical programs, particularly the Phase 2b trial for eblasakimab, targeting moderate-to-severe atopic dermatitis, with results expected in 2Q 2023. Additionally, ASLAN plans to initiate a Phase 2 trial for farudodstat in skin autoimmune diseases in the first half of 2023.
- Participation in major conferences offers visibility to investors.
- Development of eblasakimab could lead to a first-in-class treatment for atopic dermatitis.
- Upcoming topline readout for eblasakimab expected in 2Q 2023.
- Initiation of Phase 2 trial for farudodstat planned for H1 2023.
- None.
SAN MATEO, Calif. and SINGAPORE, Dec. 16, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the Company’s participation in upcoming conferences for January 2023. Listed below are meetings that management will be attending around the week of the J.P. Morgan 41st Annual Healthcare Conference.
BIO Partnering Conference
ASLAN Pharmaceuticals management will be attending this conference in San Francisco held from January 9 to January 13, 2023, at the Marriott Marquis and participating in on-on-one meetings with investors and prospective partners via the BIO Partnering online partnering platform.
To register to meet with management at this conference, visit this link.
12th Annual LifeSci Partners Corporate Access Event
ASLAN Pharmaceuticals management will be participating in this event in San Francisco on January 10, 2023, and hosting one-on-one meetings with institutional investors. To request a meeting with management, please do so through this link.
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is developing eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor in moderate-to-severe atopic dermatitis (AD) with the potential to improve upon current biologics used to treat allergic disease. Eblasakimab is being investigated in a global Phase 2b trial of moderate-to-severe AD patients with topline readout expected in 2Q 2023. ASLAN is also developing farudodstat, a potent next-generation oral inhibitor of DHODH, and plans to initiate a Phase 2 trial in skin autoimmune disease in the first half of 2023. ASLAN has teams in San Mateo, California, and in Singapore. For additional information please visit www.aslanpharma.com or follow ASLAN on LinkedIn.
Media and IR contacts
| Emma Thompson Spurwing Communications Tel: +65 6206 7350 Email: ASLAN@spurwingcomms.com | Ashley R. Robinson LifeSci Advisors, LLC Tel: +1 (617) 430-7577 Email: arr@lifesciadvisors.com |
FAQ
What events is ASLAN Pharmaceuticals participating in January 2023?
What is the main focus of ASLAN Pharmaceuticals?
What is eblasakimab and its significance for ASLAN Pharmaceuticals?
What are the upcoming clinical trial plans for ASLAN Pharmaceuticals?
What is the stock symbol for ASLAN Pharmaceuticals?
